



10 December 2021
EMA/CVMP/709072/2021
Committee for Medicinal Products for Veterinary Use

MRL summary opinion¹

Toltrazuril

Poultry eggs

On 9 December 2021 the Committee for Medicinal Products for Veterinary Use (CVMP) adopted an opinion² recommending the extension of maximum residue limits for toltrazuril to chicken eggs. Furthermore, with reference to Article 5 of Regulation (EC) No 470/2009 and in line with the criteria laid down in Commission Regulation (EU) 2017/880, the Committee agreed to extrapolate the conclusions to poultry eggs. Therefore, the Committee recommends the extension of maximum residue limits for toltrazuril in accordance with the following table:

Pharmacologically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Toltrazuril	Toltrazuril sulfone	Poultry	100 µg/kg 200 µg/kg 600 µg/kg 400 µg/kg 140 µg/kg	Muscle Skin and fat Liver Kidney Eggs	NO ENTRY	Antiparasitic agents / Agents acting against protozoa

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may request re-examination of any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to request such re-examination within 15 days of receipt of the opinion

